Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Musashino University currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This 1 action is assigned to 1 distinct examiner, representing the only active examiner interaction for the portfolio's pending matters. The prosecution is also limited to 1 distinct art unit. The busiest examiner for the portfolio is WANG, CHANG YU, who holds 1 busiest examiner pending action. This examiner is responsible for the 1 pending office action currently active for Musashino University.
The prosecution profile is focused, with all pending activity occurring within 1 art unit and under 1 examiner. This suggests that the university's current patenting efforts are concentrated on a specific technical innovation within Biotechnology & Pharmaceuticals. The outcome of the 1 pending office action will depend on the evaluation by WANG, CHANG YU. Practitioners should note that the lack of diversity in examiner assignment means the university cannot compare different perspectives on its technical claims. Future filings may benefit from targeting additional art units to spread risk across more than 1 examiner. Strategy should focus on navigating the requirements of WANG, CHANG YU to secure the 1 pending action. The university's immediate success in the Biotechnology & Pharmaceuticals sector is tied to this 1 active prosecution path.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WANG, CHANG YU | 1 | 33.4% | +53.7% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18560442 | PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING DISORDER ASSOCIATED WITH ADMINISTRATION OF ANTICANCER AGENT | WANG, CHANG YU | — |
| Art Unit | Apps |
|---|---|
| 1675 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18560442 | PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING DISORDER ASSOCIATED WITH ADMINISTRATION OF ANTICANCER AGENT | WANG, CHANG YU | 1675 | §102 | Non-Final OA | — | Pending | Nov 13, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMusashino University has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Chang Yu Wang has the most, with 1 of Musashino University's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
